Oppenheimer Cuts CalciMedica (NASDAQ:CALC) Price Target to $10.00

CalciMedica (NASDAQ:CALC) had its target price cut by Oppenheimer from $20.00 to $10.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

CALC has been the subject of several other reports. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, January 29th. Wall Street Zen upgraded CalciMedica to a “sell” rating in a research note on Saturday, January 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.00.

CalciMedica Trading Down 2.6%

CalciMedica stock traded down $0.02 during trading hours on Thursday, hitting $0.61. The company had a trading volume of 202,372 shares, compared to its average volume of 1,637,055. The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The firm has a market cap of $8.75 million, a P/E ratio of -0.38 and a beta of 0.60. The company has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $3.36. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share for the quarter. On average, sell-side analysts anticipate that CalciMedica will post -2.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CALC. Jane Street Group LLC purchased a new position in shares of CalciMedica in the 4th quarter valued at approximately $127,000. Sound View Wealth Advisors Group LLC purchased a new stake in CalciMedica during the 2nd quarter worth approximately $32,000. Cetera Investment Advisers increased its stake in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares in the last quarter. Atria Investments Inc increased its stake in CalciMedica by 20.0% during the 2nd quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock valued at $72,000 after purchasing an additional 7,436 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new position in shares of CalciMedica in the fourth quarter worth $302,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.